NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER, P. SOUCEK, Lenka RADOVÁ, Ondřej SLABÝ, Igor KISS, J. VONDRACEK, A. SPICAKOVA, Lucia BOHOVICOVÁ, P. FABIAN, Z. KALA a V. PALICKA. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Online. Biochemical Pharmacology. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2020, roč. 177, JUL, s. 113912-113922. ISSN 0006-2952. Dostupné z: https://dx.doi.org/10.1016/j.bcp.2020.113912. [citováno 2024-04-24]
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450
Autoři NEKVINDOVA, J., A. MRKVICOVA, V. ZUBANOVA, A.H. VACULOVA, P. ANZENBACHER, P. SOUCEK, Lenka RADOVÁ (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí), J. VONDRACEK, A. SPICAKOVA, Lucia BOHOVICOVÁ (203 Česká republika, domácí), P. FABIAN, Z. KALA a V. PALICKA
Vydání Biochemical Pharmacology, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2020, 0006-2952.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.858
Kód RIV RIV/00216224:14740/20:00118001
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1016/j.bcp.2020.113912
UT WoS 000541248000005
Klíčová slova anglicky Hepatocellular carcinoma; Cytochrome P450; CYP; Drug metabolism; Gene expression; Non-coding RNA
Štítky 14110513, 14110811, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Pavla Foltynová, Ph.D., učo 106624. Změněno: 25. 1. 2021 10:34.
Anotace
Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).
VytisknoutZobrazeno: 24. 4. 2024 10:15